NovaBridge Biosciences (NBP) Total Current Liabilities (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Total Current Liabilities data on file, last reported at $26.9 million in Q4 2025.

• Quarterly Total Current Liabilities rose 218.12% year-over-year to $26.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.9 million (up 218.12% YoY) and the FY2025 annual result came in at $26.9 million, up 218.12% from the prior year.
• Total Current Liabilities grew to $26.9 million in Q4 2025 per NBP's latest filing, from $16.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $97.6 billion in Q4 2021 and bottomed at $7.3 million in Q2 2025.
• The 5-year median for Total Current Liabilities is $26.9 million (2025), against an average of $7.5 billion.
• The widest annual swing landed in 2021, when Total Current Liabilities jumped 112170.09%; it then slumped 99.89% in 2022.
• Tracing NBP's Total Current Liabilities over 5 years: stood at $97.6 billion in 2021, then tumbled by 99.89% to $106.6 million in 2022, then sank by 46.35% to $57.2 million in 2023, then plunged by 85.22% to $8.5 million in 2024, then jumped by 218.12% to $26.9 million in 2025.
• Per Business Quant, the three latest NBP Total Current Liabilities figures stand at $26.9 million (Q4 2025), $16.1 million (Q3 2025), and $7.3 million (Q2 2025).

Peer Comparison